Two NMIN researchers based at the University of British Columbia (UBC) have been awarded CIHR funding to support projects addressing COVID19-related health challenges.
NMIN’s Scientific Director, Dr. Pieter Cullis, was awarded $237,445 in support of his effort to develop an antibody therapy for COVID-19. The project, seed-funded by NMIN, will use lipid nanoparticles to carry genetic instructions for the antibody to the liver, resulting in the secretion of antibodies that target the SARS-CoV-2 virus.
NMIN researcher Dr. Robert Hancock was awarded $422,084 to lead a project using genomic methods and next-generation RNA sequencing technology to determine which COVID-19 patients are at higher risk of developing life-threatening sepsis.